Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
Portfolio Pulse from Benzinga Newsdesk
Affimed N.V. (NASDAQ:AFMD) has received FDA clearance for its IND application to initiate a Phase 2 clinical trial for the combination of AFM13 and Artiva Biotherapeutics' AB-101. The trial, AFM13-203 (LuminICE-203), will evaluate the safety and efficacy of the combination therapy in patients with r/r cHL and CD30-positive PTCL. The study is set to begin in Q3 2023, with data from the safety run-in phase expected in H1 2024.
May 23, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed has received FDA clearance for its IND application to initiate a Phase 2 clinical trial for the combination of AFM13 and AB-101, with the study set to begin in Q3 2023.
The FDA clearance for the IND application is a positive development for Affimed, as it allows the company to proceed with the Phase 2 clinical trial for the combination therapy. This could potentially lead to a new treatment option for patients with r/r cHL and CD30-positive PTCL, which may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100